215 results
Page 3 of 11
8-K
EX-99.1
lkn r0knw120xs
10 Nov 22
VBI Vaccines Reports Third Quarter 2022 Financial Results and Provides Corporate Update
8:00am
8-K
EX-99.1
lvx8p
12 Oct 22
Regulation FD Disclosure
8:00am
8-K
EX-99.1
ds7 tt1uota
29 Sep 22
VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901
8:00am
8-K
EX-99.1
bwhqjzt08ql4
15 Sep 22
VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures
5:01pm
8-K
EX-99.1
wp0u6w9a
8 Sep 22
Regulation FD Disclosure
6:10am
8-K
EX-99.1
ofbrf fw3s
8 Aug 22
VBI Vaccines Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8:01am
8-K
EX-99.1
mp79itmhfbl
12 Jul 22
VBI Vaccines Announces Appointment of John Dillman as Chief Commercial Officer
8:00am
8-K
EX-99.1
lldre2a w6wbhr
28 Jun 22
VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hepatitis B Vaccine Presented at EASL 2022
8:00am
8-K
EX-99.1
8geyupogl8 18ys8
1 Jun 22
VBI Vaccines Announces UK MHRA Marketing Authorisation for PreHevbri™, a 3-Antigen
8:00am
8-K
EX-99.1
4cxhe
19 May 22
Regulation FD Disclosure
8:00am
8-K
EX-99.1
yihd opwq
9 May 22
VBI Vaccines Reports First Quarter 2022 Financial Results and Provides Corporate Update
8:00am
8-K
EX-99.1
s8t25 8xxdbvky5exkq
2 May 22
VBI Vaccines Announces European Commission Marketing Authorisation for PreHevbri™, a 3-Antigen Adult Hepatitis B Vaccine
8:00am
8-K
EX-99.1
t5l1w14g
5 Apr 22
VBI Vaccines Announces New Data and Progress of VBI-2900, VBI’s eVLP Coronavirus Program
8:00am
8-K
EX-99.1
4nk7xw
29 Mar 22
VBI Vaccines Announces PreHevbrio™ is Now Available in the United States for the Prevention of Hepatitis B in Adults
8:00am